Abdulla Watad1,2, Mark Kacar1,3, Nicola Luigi Bragazzi4, Qiao Zhou1,5, Miriam Jassam3, Jan Taylor6, Eve Roman7, Alexandra Smith7, Richard A Jones8, Howard Amital2, Catherine Cargo8, Dennis McGonagle1, Sinisa Savic1,3. 1. National Institute for Health Research-Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James's University Hospital, Leeds, United Kingdom. 2. Department of Medicine B and Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 3. Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, United Kingdom. 4. Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, ON, Canada. 5. Department of Rheumatology & Immunology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China. 6. Department of Haematology, St James's University Hospital, Leeds, United Kingdom. 7. Epidemiology & Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom. 8. HMDS Department, Leeds Teaching Hospitals, Leeds, United Kingdom.
Abstract
Objectives: We theorized that myelodysplastic syndrome (MDS) with somatic mutations and karyotype abnormalities are associated with autoinflammation, and that the presence of autoinflammatory disease affected prognosis in MDS. Methods: One hundred thirty-four MDS patients were assessed for the prevalence of autoinflammatory complications and its link with karyotypes and somatic mutation status. Autoinflammatory complications were described either as well-defined autoinflammatory diseases (AD) or undifferentiated "autoinflammatory disease" (UAD) (defined as CRP over 10.0 mg/L on five consecutive occasions, taken at separate times and not explained by infection). Several patient characteristics including demographic, clinical, laboratory, cytogenetics charts, and outcomes, were compared between different groups. Results: Sixty-two (46.3%) patients had an autoinflammatory complication manifesting as arthralgia (43.5% vs. 23.6%, p = 0.0146), arthritis (30.6% vs. 15.3%, p = 0.0340), skin rash (27.4% vs. 12.5%, p = 0.0301), pleuritis (14.5% vs. 4.2%, p = 0.0371) and unexplained fever (27.4% vs. 0%, p < 0.0001). AD were found in 7.4% of MDS patients (with polymyalgia rheumatic being the most frequently one). Classical autoimmune diseases were found only in 4 MDS patients (3.0%). Transcription factor pathway mutations (RUNX1, BCOR, WTI, TP53) (OR 2.20 [95%CI 1.02-4.75], p = 0.0451) and abnormal karyotypes (OR 2.76 [95%CI 1.22-6.26], p = 0.0153) were associated with autoinflammatory complications. Acute leukaemic transformation was more frequent in MDS patients with autoinflammatory features than those without (27.4% vs. 9.7%, p = 0.0080). Conclusions: Autoinflammatory complications are common in MDS. Somatic mutations of transcription factor pathways and abnormal karyotypes are associated with greater risk of autoinflammatory complications, which are themselves linked to malignant transformation and a worse prognosis.
Objectives: We theorized that myelodysplastic syndrome (MDS) with somatic mutations and karyotype abnormalities are associated with autoinflammation, and that the presence of autoinflammatory disease affected prognosis in MDS. Methods: One hundred thirty-four MDSpatients were assessed for the prevalence of autoinflammatory complications and its link with karyotypes and somatic mutation status. Autoinflammatory complications were described either as well-defined autoinflammatory diseases (AD) or undifferentiated "autoinflammatory disease" (UAD) (defined as CRP over 10.0 mg/L on five consecutive occasions, taken at separate times and not explained by infection). Several patient characteristics including demographic, clinical, laboratory, cytogenetics charts, and outcomes, were compared between different groups. Results: Sixty-two (46.3%) patients had an autoinflammatory complication manifesting as arthralgia (43.5% vs. 23.6%, p = 0.0146), arthritis (30.6% vs. 15.3%, p = 0.0340), skin rash (27.4% vs. 12.5%, p = 0.0301), pleuritis (14.5% vs. 4.2%, p = 0.0371) and unexplained fever (27.4% vs. 0%, p < 0.0001). AD were found in 7.4% of MDSpatients (with polymyalgia rheumatic being the most frequently one). Classical autoimmune diseases were found only in 4 MDSpatients (3.0%). Transcription factor pathway mutations (RUNX1, BCOR, WTI, TP53) (OR 2.20 [95%CI 1.02-4.75], p = 0.0451) and abnormal karyotypes (OR 2.76 [95%CI 1.22-6.26], p = 0.0153) were associated with autoinflammatory complications. Acute leukaemic transformation was more frequent in MDSpatients with autoinflammatory features than those without (27.4% vs. 9.7%, p = 0.0080). Conclusions: Autoinflammatory complications are common in MDS. Somatic mutations of transcription factor pathways and abnormal karyotypes are associated with greater risk of autoinflammatory complications, which are themselves linked to malignant transformation and a worse prognosis.
Authors: Juliana Schwaab; Thomas Ernst; Philipp Erben; Jenny Rinke; Susanne Schnittger; Philipp Ströbel; Georgia Metzgeroth; Max Mossner; Torsten Haferlach; Nicholas C P Cross; Andreas Hochhaus; Wolf-Karsten Hofmann; Andreas Reiter Journal: Ann Hematol Date: 2012-08-10 Impact factor: 3.673
Authors: Marc H G P Raaijmakers; Siddhartha Mukherjee; Shangqin Guo; Siyi Zhang; Tatsuya Kobayashi; Jesse A Schoonmaker; Benjamin L Ebert; Fatima Al-Shahrour; Robert P Hasserjian; Edward O Scadden; Zinmar Aung; Marc Matza; Matthias Merkenschlager; Charles Lin; Johanna M Rommens; David T Scadden Journal: Nature Date: 2010-03-21 Impact factor: 49.962
Authors: Paula Savola; Sofie Lundgren; Mikko A I Keränen; Henrikki Almusa; Pekka Ellonen; Marjatta Leirisalo-Repo; Tiina Kelkka; Satu Mustjoki Journal: Blood Cancer J Date: 2018-07-26 Impact factor: 11.037
Authors: James A Poulter; Jason C Collins; Catherine Cargo; Ruth M De Tute; Paul Evans; Daniela Ospina Cardona; David T Bowen; Joanna R Cunnington; Elaine Baguley; Mark Quinn; Michael Green; Dennis McGonagle; David B Beck; Achim Werner; Sinisa Savic Journal: Blood Date: 2021-07-01 Impact factor: 25.476